{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:47Z","timestamp":1791404147601,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40259-022-00554-6","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T09:03:35Z","timestamp":1663405415000},"page":"761-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog\u00ae) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Thomas C.","family":"Blevins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Raiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxann","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Chullikana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmikant","family":"Vashishta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-3354","authenticated-orcid":false,"given":"Gopinath","family":"Ranganna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"issue":"14","key":"554_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386. https:\/\/doi.org\/10.1056\/NEJM199309303291401.","journal-title":"N Engl J Med"},{"issue":"5","key":"554_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1056\/NEJM199307293290502","volume":"329","author":"P Reichard","year":"1993","unstructured":"Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304\u20139. https:\/\/doi.org\/10.1056\/NEJM199307293290502.","journal-title":"N Engl J Med"},{"issue":"1","key":"554_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40265-015-0500-0","volume":"76","author":"K Hermansen","year":"2016","unstructured":"Hermansen K, Bohl M, Schioldan AG. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs. 2016;76(1):41\u201374. https:\/\/doi.org\/10.1007\/s40265-015-0500-0.","journal-title":"Drugs"},{"key":"554_CR4","doi-asserted-by":"publisher","unstructured":"American Diabetes Association 2019 Criteria: classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13\u2013S28. https:\/\/doi.org\/10.2337\/dc19-S002.","DOI":"10.2337\/dc19-S002"},{"key":"554_CR5","unstructured":"European Medicines Agency (EMA): guideline on similar biological medicinal products. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. Accessed 15 Sept 2021."},{"key":"554_CR6","unstructured":"US Department of Health and Human Services. US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291128.pdf. Accessed 15 Sept 2021."},{"key":"554_CR7","unstructured":"Expert Committee on Biological Standardization, World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Microsoft Word-BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.doc (who.int). Accessed 15 Sept 2021."},{"key":"554_CR8","doi-asserted-by":"publisher","unstructured":"Cefalu T, Dawes DE, Gavlak G, et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Diabetes Care. 2018;41;1299\u2013311. https:\/\/doi.org\/10.2337\/dci18-0019.","DOI":"10.2337\/dci18-0019"},{"key":"554_CR9","unstructured":"Kixelle (insulin aspart) EPAR medicine overview (European public assessment\u00a0report). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kixelle-epar-public-assessment-report_en.pdf. Accessed 15 Sept 2021."},{"key":"554_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14519","author":"U H\u00f6velmann","year":"2021","unstructured":"H\u00f6velmann U, Raiter Y, Chullikana A, et al. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: a randomized, double-blind, crossover, euglycaemic glucose clamp study. Diabetes Obes Metab. 2021. https:\/\/doi.org\/10.1111\/dom.14519.","journal-title":"Diabetes Obes Metab"},{"key":"554_CR11","unstructured":"International Ethical Guidelines for Biomedical Research Involving Human Patients (Council for International Organizations of Medical Sciences 2002). Replaced in 2016 as International ethical guidelines for health-related research involving humans. CIOMS. WEB-CIOMS-EthicalGuidelines.pdf. Accessed 15 Sept 2021."},{"key":"554_CR12","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Topic E6 (R1) Guideline for good clinical practice. 2002. E6 Step 5 Good clinical practice R1 (europa.eu). https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 15 Sept 2021."},{"key":"554_CR13","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects\u2014last amended by the 64th WMA general assembly, Fortaleza, Brasil. 2013. Declaration of Helsinki\u2013Ethical Principles for Medical Research Involving Human Subjects\u2013WMA\u2013The World Medical Association. Accessed 15 Sept 2021."},{"issue":"4","key":"554_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPSJ. 2014;16(4):658\u201373. https:\/\/doi.org\/10.1208\/s12248-014-9599-2.","journal-title":"AAPSJ."},{"issue":"2","key":"554_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/dia.2019.0382","volume":"22","author":"SK Garg","year":"2020","unstructured":"Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized open-label trial (GEMELLI 1). Diabetes Technol Ther. 2020;22(2):85\u201395. https:\/\/doi.org\/10.1089\/dia.2019.0382.","journal-title":"Diabetes Technol Ther"},{"key":"554_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"American Diabetes Association Workgroup on Hypoglycemia","year":"2005","unstructured":"American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245\u20139. https:\/\/doi.org\/10.2337\/diacare.28.5.1245.","journal-title":"Diabetes Care"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36:1384\u201395. https:\/\/doi.org\/10.2337\/dc12-2480.","journal-title":"Diabetes Care"},{"key":"554_CR18","unstructured":"US Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection guidance for industry. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection guidance for industry (fda.gov). 2019. https:\/\/www.fda.gov\/media\/119788\/download. Accessed 13 Aug 2021."},{"issue":"5","key":"554_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1208\/s12248-017-0107-3","volume":"19","author":"V Devanarayan","year":"2017","unstructured":"Devanarayan V, Smith WC, Brunelle RL, Seger ME, Krug K, Bowsher RR. Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J. 2017;19(5):1487\u201398. https:\/\/doi.org\/10.1208\/s12248-017-0107-3.","journal-title":"AAPS J"},{"key":"554_CR20","first-page":"289","volume-title":"Detection and quantification of antibodies to biopharmaceuticals","author":"V Devanarayan","year":"2011","unstructured":"Devanarayan V, Tovey MG. Cut points and performance characteristics for anti-drug antibody assays. In: Tovey MG, editor. Detection and quantification of antibodies to biopharmaceuticals. West Sussex: Wiley; 2011. p. 289\u2013308."},{"issue":"5","key":"554_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/s0197-2456(02)00222-2","volume":"23","author":"SC Chow","year":"2002","unstructured":"Chow SC, Shao J. A note on statistical methods for assessing therapeutic equivalence. Control Clin Trial. 2002;23(5):515\u201320. https:\/\/doi.org\/10.1016\/s0197-2456(02)00222-2.","journal-title":"Control Clin Trial"},{"key":"554_CR22","doi-asserted-by":"publisher","unstructured":"McMullan T. Sample size calculation in clinical research. In: Chow S-C, Shao J, Wang H (2003) ISBN 0824709705. 2004. Dekker; Pharmaceutical Statistics, vol. 3, pp. 227\u20138. https:\/\/doi.org\/10.1002\/PST.127.","DOI":"10.1002\/PST.127"},{"issue":"421","key":"554_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2307\/2290705","volume":"88","author":"RJA Little","year":"1993","unstructured":"Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc. 1993;88(421):125\u201334. https:\/\/doi.org\/10.2307\/2290705.","journal-title":"J Am Stat Assoc"},{"key":"554_CR24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 03 Dec 2021."},{"issue":"12","key":"554_CR25","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696\u2013705. https:\/\/doi.org\/10.1002\/bit.26438.","journal-title":"Biotechnol Bioeng"},{"key":"554_CR26","unstructured":"US Food and Drug Administration. Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act November 2019 https:\/\/www.fda.gov\/media\/133014\/download. Accessed 25 Nov 2021. European Medicines Agency (EMA): guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (europa.eu). Accessed 04 Aug 2022."},{"key":"554_CR27","unstructured":"Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on similar medicinal products containing recombinant human soluble insulin (EMEA\/CHMP\/BMWP\/32775\/2005). 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins_en-0.pdf. Accessed 15 Sept 2021."},{"issue":"2","key":"554_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/dia.2017.0373","volume":"20","author":"P Home","year":"2018","unstructured":"Home P, Derwahl KM, Ziemen M, et al. Anti-insulin antibodies and adverse events with biosimilar insulin lispro compared with humalog insulin lispro in people with diabetes. Diabetes Technol Ther. 2018;20(2):160\u201370. https:\/\/doi.org\/10.1089\/dia.2017.0373.","journal-title":"Diabetes Technol Ther"},{"key":"554_CR29","unstructured":"Novo Nordisk: NovoLog, insulin aspart injection 100 units\/mL, Novo Nordisk. Prescribing information revised: 2021. https:\/\/www.novopi.com\/novolog.pdf. Accessed 01 Dec 2021."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00554-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T22:39:12Z","timestamp":1668119952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00554-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was sponsored by Mylan GmbH, Switzerland (now Viatris), and Biocon Biologics Ltd, Bengaluru, India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas C. Blevins has received clinical research support from AstraZeneca, Eli Lilly, Lexicon, Merck, Mylan, Novo Nordisk, Sanofi, Mannkind, Medtronic, and Tandem and speaker fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Janssen, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Bin Sun, Charles Donnelly, Roxann Shapiro, Gopinath Ranganna, and Abhijit Barve are employees of Viatris Inc. and may hold stock or stock options in the company. Yaron Raiter is an ex-employee of Viatris Inc and currently associated with GE Healthcare. Anoop Chullikana and Anita Rao are Biocon Biologics Ltd employees and may hold stock or stock options in the company. Laxmikant Vashishta is an ex-employee of Biocon Biologics Ltd. and currently a full-time employee of Alvogen Pharma India Pvt. Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The conduct of this study was in accordance with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, and the appropriate regulatory requirements in the countries in which the study was conducted. The protocol and its amendments and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants voluntarily consented to participate and signed an Institutional Review Board\/Independent Ethics Committee approved informed consent form prior to study inclusion.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TCB, YR, BS, CD, RS, AC, GR, and AB contributed to the conception and design of the study; acquisition, analysis, and interpretation of data; and critically revising the manuscript for important intellectual content. YR and GR contributed to the analysis and interpretation of data; drafting of the manuscript; and critically revising the manuscript for important intellectual content. CD, AR, and LV contributed to acquisition, analysis, and interpretation of data. All authors reviewed and approved the manuscript for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}